

Tadalafil: effects on blood pressure and arterial stiffness in systolic hypertension

Submission date 30/09/2004	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 30/09/2004	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 10/09/2008	Condition category Circulatory System	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ian B Wilkinson

Contact details
Clinical Pharmacology Unit
Level 3, ACCI
Box 110
Addenbrooke's NHS Trust
Cambridge
United Kingdom
CB2 2QQ
+44 (0)1223 336806
ibw20@cam.ac.uk

Additional identifiers

Protocol serial number
N0544129338

Study information

Scientific Title

Study objectives

Does the selective phosphodiesterase-5 inhibitor tadalafil reduce arterial stiffness and blood pressure in systolic hypertension?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hypertension

Interventions

The project will assess the effects of a single dose of the selective phosphodiesterase-5 inhibitor tadalafil on arterial stiffness and blood pressure in patients with systolic hypertension. Subjects will visit the Vascular Research Clinics for a screening visit and two study visits and will receive either placebo or tadalafil on each study visit. Measurements of blood pressure and arterial stiffness will be made at baseline and at hourly intervals for four hours following administration of the drug or placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Tadalafil

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

10/08/2006

Eligibility

Key inclusion criteria

15 subjects over 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

11/08/2003

Date of final enrolment

10/08/2006

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Clinical Pharmacology Unit

Cambridge

United Kingdom

CB2 2QQ

Sponsor information**Organisation**

Department of Health

Funder(s)

Funder type

Government

Funder Name

Cambridge Consortium - Addenbrooke's (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration